Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Lung cancer deaths by type of treatment

Principal Investigator
Name
David Gierada
Degrees
MD
Institution
Washington University
Position Title
Professor of Radiology
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-425
Initial CDAS Request Approval
Jul 10, 2018
Title
Lung cancer deaths by type of treatment
Summary
Lung cancer screening guidelines endorse screening for persons able and willing to undergo curative therapy. However, the ability to undergo curative therapy may not be thoroughly assessed prior to referral for screening. Thus some persons with screen-diagnosed lung cancers are unable to receive curative therapy. This project will examine the impact of the type of treatment on lung cancer death rates in persons with the same stage of disease.
Aims

1. Compare lung cancer death rates for lung cancers of the same stage by type of treatment, for the entire NLST cohort and separately for the CT and CXR randomization arms.
2. Determine whether differences in treatment and lung cancer death rates are associated with participant, screen, diagnostic follow-up, and lung cancer pathology characteristics.

Collaborators

Paul Pinsky, PhD

Related Publications